BNC105P, a vascular disrupting agent, is a disodium phosphate ester prodrug of BNC105. BNC105P is a tubulin polymerization inhibitor that suppresses cancer cell proliferation. BNC105P participated in phase I/II trial for patients with metastatic renal cell carcinoma. Although the primary endpoint was not met in an unselected population, correlative studies suggested several biomarkers that warrant further prospective evaluation. Besides, BNC105P was involved in phase II clinical trial as second-line chemotherapy for advanced malignant pleural mesothelioma. The drug was safe and tolerable, but the sole response was insufficient to warrant further research as a single agent. In addition, BNC105P in combination with Ibrutinib was studied in phase I trials for patients with chronic lymphocytic leukemia to determine the preliminary assessment of the efficacy.

MK-2206 is an oral selective allosteric inhibitor of Akt that targets all three isoforms of human Akt (Akt-1, Akt-2 and Akt-3). In a phase I study of solid tumors, MK-2206 demonstrated evidence of target modulation and anti-proliferative activity as a single agent and in combination with other agents. Current ongoing trials of MK-2206 include monotherapy and combination therapy in breast cancer, colorectal cancer, haematological malignancies, non-small cell lung cancer and other. Detected treatment-related adverse event are: rash, fatigue, hyperglycemia.

Veribulin is a novel microtubule destabilizer that both functions as a potent cytotoxin and acts as a vascular disrupting agent (VDA). It binds to the same (or nearby) sites on β-tubulin as colchicine. It is capable of evading multidrug resistance pumps and, thus, achieves high CNS concentrations. It is efficacious in multiple xenograft models without CNS toxicity. Veribulin had previously demonstrated pre-clinical and clinical activity in multiple tumor types. Veribulin is in phase II clinical trial for the treatment of Glioblastoma and Malignant melanoma.